Trial Profile
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2021
Price :
$35
*
At a glance
- Drugs Lifitegrast (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Shire
- 19 Jun 2014 New trial record